SynAgile Corporation   Report issue

For profit Phase 2
Founded: Piedmont CA United States (2011)
Status: No NME R&D (2011)

Organization Overview

First Clinical Trial
2015
NCT02763137
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

SynAgile Corporation

Active Ingredients

Drugs in Phase 2 Trials (2)

carbidopa (sinemet) (2 trials)

levodopa (larodopa) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Parkinson Disease (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2